BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dal Bello G, Gisondi P, Idolazzi L, Girolomoni G. Psoriatic Arthritis and Diabetes Mellitus: A Narrative Review. Rheumatol Ther 2020;7:271-85. [PMID: 32306243 DOI: 10.1007/s40744-020-00206-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Tarannum S, Leung YY, Johnson SR, Widdifield J, Strand V, Rochon P, Eder L. Sex- and gender-related differences in psoriatic arthritis. Nat Rev Rheumatol 2022. [PMID: 35927578 DOI: 10.1038/s41584-022-00810-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Alnaqbi KA, Hannawi S, Namas R, Alshehhi W, Badsha H, Al-Saleh J. Consensus statements for pharmacological management, monitoring of therapies, and comorbidity management of psoriatic arthritis in the United Arab Emirates. Int J Rheum Dis 2022. [PMID: 35916205 DOI: 10.1111/1756-185X.14406] [Reference Citation Analysis]
3 Infante M, Padilla N, Alejandro R, Caprio M, Della-morte D, Fabbri A, Ricordi C. Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents. Medicina 2022;58:571. [DOI: 10.3390/medicina58050571] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ciaffi J, Mele G, Mancarella L, Brusi V, Lisi L, Faranda Cordella J, Lubrano E, D'angelo S, Meliconi R, Ursini F. Prevalence of Type 2 and Type 1 Diabetes in Psoriatic Arthritis. J Clin Rheumatol 2022;28:e324-e329. [DOI: 10.1097/rhu.0000000000001706] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Gialouri CG, Evangelatos G, Fragoulis GE. Choosing the Appropriate Target for the Treatment of Psoriatic Arthritis: TNFα, IL-17, IL-23 or JAK Inhibitors? Mediterr J Rheumatol 2022;33:150-61. [PMID: 36127928 DOI: 10.31138/mjr.33.1.150] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ikumi K, Torii K, Sagawa Y, Kanayama Y, Nakada A, Nishihara H, Morita A. Phosphodiesterase 4 inhibitor apremilast improves insulin resistance in psoriasis patients. J Dermatol 2021. [PMID: 34961971 DOI: 10.1111/1346-8138.16286] [Reference Citation Analysis]
7 Novelli L, Lubrano E, Venerito V, Perrotta FM, Marando F, Curradi G, Iannone F. Extra-Articular Manifestations and Comorbidities in Psoriatic Disease: A Journey Into the Immunologic Crosstalk. Front Med (Lausanne) 2021;8:737079. [PMID: 34631754 DOI: 10.3389/fmed.2021.737079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Karmacharya P, Ogdie A, Eder L. Psoriatic arthritis and the association with cardiometabolic disease: a narrative review. Ther Adv Musculoskelet Dis 2021;13:1759720X21998279. [PMID: 33737966 DOI: 10.1177/1759720X21998279] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 15.0] [Reference Citation Analysis]